All News

Robert Motzer, MD, led an expert panel to discuss the phase 3 CONTACT-03 which examined patients with renal cell carcinoma.

Baseline characteristics do not appear to correlate with long-term benefits for patients receiving durvalumab plus tremelimumab and chemotherapy for metastatic non–small cell lung cancer in the phase 3 POSEIDON trial.

Ryan Jacobs, MD, and Alan Pierre Zausner Skarbnik, MD, discussed the use of acalabrutinib and zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

With the approval of momelotinib by the FDA, the updated use for its role in myelofibrosis will potentially change clinical practice, according to Ruben Mesa, MD.

Patients with myelofibrosis and anemia can now receive treatment with momelotinib following the agent’s approval by the FDA based on results from the phase 3 MOMENTUM trial.

Investigators report no differences in progression-free survival among patients with nonseminomatous testicular cancer who received surveillance or adjuvant chemotherapy in a cohort study.

Findings from the phase 3 AEGEAN trial suggest that patients with EGFR-mutated non–small cell lung cancer experience similar outcomes whether receiving durvalumab or placebo.

Data from the phase 2 JACKPOT8 PARTB study support the new drug application for golidocitinib as a treatment for relapsed/refractory peripheral T-cell lymphoma in China.

CancerNetwork hosted a Training Academy focused on sequencing therapies for patients with multiple myeloma who are treated with bispecific antibodies.

The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.

Across several clinical trials, Unfold AI appears to help in prostate cancer treatment selection and follow-up.

Prescribing information has been updated to include temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma or refractory anaplastic astrocytoma.

Treatment with adagrasib appears to be particularly well tolerated in patients with KRAS G12C–mutated non–small cell lung cancer who receive it for more than 1 year.

Data from a phase 1/2 trial support the fast track designation for tulmimetostat as a treatment for patients with ARID1A-mutated advanced, recurrent or metastatic endometrial cancer.

Iruplinalib appears tolerable with no new safety signals among patients with locally advanced and metastatic ALK-positive non–small cell lung cancer in the phase 3 INSPIRE trial.

Co-editor-in-chief, Howard S. Hochster, MD, reviews the ongoing drug price negotiations and the effect it will have in the health care space.

Data from the phase 2 EVOKE-02 trial support further assessment of sacituzumab govitecan plus pembrolizumab as a frontline treatment for metastatic non–small cell lung cancer.

Investigators report acceptable morbidity and health-related quality of life with neoadjuvant chemotherapy plus surgery and concomitant chemoradiotherapy in those with cervical cancer.

Allogeneic stem cell transplant should be strongly considered as a treatment for patients with mantle cell lymphoma who are adequately fit, according to Thomas E. Lew.

Benmelstobart plus anlotinib and chemotherapy produce survival benefits in extensive-stage small cell lung cancer across all patient subgroups in the phase 3 ETER701 trial.

Investigators report a progression-free survival benefit with osimertinib plus chemotherapy in EGFR-mutated non–small cell lung cancer across all subgroups in the phase 3 FLAURA2 study.

Investigators will assess AFM13 in combination with AB-101 as a treatment for those with relapsed or refractory Hodgkin lymphoma in the phase 2 LuminICE-203 trial.

Findings suggest the presence of different genetic pathways that may drive disparities in outcomes between Black and White patients with endometrioid endometrial cancer, according to Kristin Taylor, MD.

Characteristics including Ogata score and phenotypic aberrancies may correlate with mutational patterns that are predictive of treatment response in patients with myelodysplastic syndrome.

Findings from the phase 3 THOR study support the marketing authorization application for erdafitinib as a treatment for those with advanced or metastatic urothelial cancer harboring FGFR3 alterations.

Treatment with loncastuximab tesirine-lpyl in the safety run-in portion of the LOTIS-5 study appears to be promising, according to Michal Kwiatek, MD, PhD

A single dose of motixafortide results in achievement of stem cell collection goal in patients with multiple myeloma.

Bispecific antibodies may be more broadly applicable as treatment for patients with multiple myeloma in the short-term, according to Ajai Chari, MD.

Asciminib may be more tolerable than bosutinib in the treatment of those with chronic myeloid leukemia, according to Michael Deininger, MD.

Data from previous studies demonstrate that pretreatment levels of circulating tumor DNA may be prognostic in diffuse large B-cell lymphoma, according to Mark J. Roschewski, MD.